Latest Ratios: P/E Ratio -77.9x · EV/EBITDA N/A · ROE -42.5%. (2003–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9.2B | $13.1B | $6.6B | $4.3B | $5.0B | $1.4B | $1.7B | $1.4B | $1.7B | $1.1B | $78M |
| Enterprise Value | $9.4B | $13.2B | $6.6B | $4.3B | $4.7B | $1.4B | $1.7B | $1.4B | $1.2B | $932M | $37M |
| P/E Ratio → | -77.92 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.45 | 13.63 | 36.44 | — | — | — | — | — | — | — | — |
| P/B Ratio | 14.88 | 21.68 | 8.70 | 10.67 | 25.20 | 7.15 | 7.16 | 3.37 | 3.50 | 6.17 | 2.13 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.79 | 36.55 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.1% | 94.1% | 96.5% | — | — | — | — | — | — | — | — |
| Operating Margin | -31.3% | -31.3% | -276.4% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -30.1% | -30.1% | -258.6% | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -42.5% | -42.5% | -80.3% | -124.0% | -150.1% | -110.9% | -61.6% | -18.8% | -10.0% | -28.5% | -60.8% |
| ROA | -25.0% | -25.0% | -55.4% | -74.5% | -92.9% | -86.3% | -55.5% | -18.1% | -9.7% | -26.7% | -48.2% |
| ROIC | -29.4% | -29.4% | -62.4% | -168.7% | -576.6% | -104.7% | -55.5% | -18.0% | -13.4% | -161.9% | -234.2% |
| ROCE | -32.9% | -32.9% | -71.4% | -99.0% | -132.5% | -111.0% | -62.8% | -21.2% | -12.3% | -29.2% | -90.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.59 | 0.59 | 0.16 | 0.29 | 0.25 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.26 | 0.03 | 0.04 | -1.43 | -0.18 | -0.22 | -0.11 | -1.01 | -1.05 | -1.11 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -11.92 | -11.92 | -30.76 | -28.39 | -73.51 | — | — | — | — | — | -21.63 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.01 | 4.01 | 6.10 | 5.38 | 3.12 | 3.54 | 6.13 | 17.52 | 57.46 | 19.10 | 8.58 |
| Quick Ratio | 3.77 | 3.77 | 5.90 | 5.38 | 3.12 | 3.54 | 6.13 | 17.52 | 57.46 | 19.10 | 8.58 |
| Cash Ratio | 3.17 | 3.17 | 5.47 | 5.35 | 3.10 | 3.52 | 6.10 | 17.47 | 57.29 | 19.05 | 8.44 |
| Asset Turnover | — | 0.76 | 0.17 | — | — | — | — | — | — | — | — |
| Inventory Turnover | 0.75 | 0.75 | 0.18 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 51.21 | 109.06 | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $22M | $21M | $19M | $17M | $17M | $15M | $15M | $15M | $12M | $5M |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MDGL stock.
Madrigal Pharmaceuticals, Inc.'s current P/E ratio is -77.9x. The historical average is 2.2x.
Madrigal Pharmaceuticals, Inc.'s return on equity (ROE) is -42.5%. The historical average is -76.7%.
Based on historical data, Madrigal Pharmaceuticals, Inc. is trading at a P/E of -77.9x. Compare with industry peers and growth rates for a complete picture.
Madrigal Pharmaceuticals, Inc. has 94.1% gross margin and -31.3% operating margin.
Key Metrics
Top Statement Risk
Sustainability of operating profit
Metrics are mathematically derived from official filings.
Premium Multiples Price Revenue Durability Not Earnings
Based on reported figures, MDGL trades at 9.62 times sales and 14.89 times book while trailing P/E is negative at -31.14, indicating the market is capitalizing revenue growth rather than demonstrated earnings power today.
A negative trailing P/E alongside a 9.62 price-to-sales multiple suggests investors are paying for the commercial revenue ramp rather than reported earnings, which is typical of a company only recently turning operating-positive. The 14.89 price-to-book multiple reflects an equity base heavily reduced by an accumulated deficit of roughly $2.2B, so book value offers little valuation anchor. Investors should monitor whether the 2026Q3 operating profit proves repeatable before the multiple can be reconciled to sustained earnings.
Operating Turn Rests on a Single Quarter
According to the reported income ratios, MDGL's operating margin moved from -29.8% in 2026Q1 to 13.0% in 2026Q3, but the improvement follows two loss-making quarters and remains unproven as a trend.
The swing from deeply negative operating margins to 13.0% suggests operating leverage is beginning to flow through as revenue scales, with net margin of 12.9% tracking closely. However, gross margin compressed from 96.7% to 89.0% before recovering to 91.2%, which may indicate mix or pricing pressure as the product base broadens. Earning power should be judged on a sustained run of positive quarters rather than the latest print.
Returns Recovering From Deeply Negative Territory
Based on reported figures, MDGL's ROIC improved from -13.0% in 2025Q3 to 8.0% in 2026Q3 and ROE moved to 9.6%, yet both remain low against a multi-year negative trend.
The move to positive ROIC and ROE suggests returns are moving in the right direction, but ten quarters of prior negative returns mean the trend is recent and unproven. The improvement appears driven primarily by margin recovery rather than capital efficiency, since asset turnover remains low at 0.32. Investors should watch whether ROIC can hold above its cost of capital through a full operating cycle.
Strong Current Ratio Masks Volatile Cash Base
As reported in the balance sheets, MDGL's current ratio compressed from 8.72 in 2024Q2 to 3.05 in 2026Q3, while the quick ratio of 2.78 still indicates ample short-term coverage.
Even after compression, a 3.05 current ratio and 2.78 quick ratio suggest the company holds substantial liquid assets relative to near-term obligations, with inventory dependence appearing minimal. The sharp decline from 8.72 over ten quarters may reflect rising current liabilities alongside commercial scale-up. Under severe stress, liquidity would depend heavily on cash balances that have swung materially, so investors should monitor cash levels in future filings.
Debt Rising but Coverage Now Positive
Based on reported figures, MDGL's debt-to-equity rose from 0.14 to 0.56 and interest coverage turned to 7.87 in 2026Q3 after negative readings through 2026Q2.
Debt has roughly tripled while equity contracted before recovering, lifting leverage to a moderate level, and the reported D/EBITDA of 6.28 in 2026Q3 is elevated relative to a conventional comfort threshold. The shift to positive interest coverage suggests debt service has become manageable on current operating profit, but this rests on one quarter of earnings. Refinancing and covenant exposure cannot be assessed from the supplied data and warrant further investigation.
Single-Quarter Turn May Not Persist
The most commonly misapplied metric here is trailing ROE, since MDGL's 9.6% reading in 2026Q3 relies on a single profitable quarter against ten quarters of negative returns and a shrinking equity base.
For a pre-profit commercial biotech, ROE is distorted by a small and recently rebuilt equity denominator and by the accumulated deficit, so a positive print can overstate durable returns. Operating cash flow has been erratic and working capital swings dominate quarterly results, which suggests a cash-based or revenue-run-rate measure would be more informative than headline ROE. Investors should evaluate sustained positive operating margins and cumulative free cash flow over several quarters before treating the return improvement as structural.